Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.

Bristol Myers Squibb Co. released sales and profit forecasts for 2025 below Wall Street’s expectations — a sign the company’s ...

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...

Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...

Ed: As usual, a disappointing lack of ambition from the senior management to push hard for promotion. They blame the transfer ...

BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...

Ontario County Sheriff’s deputies arrested a Fairport man at Bristol Mountain Ski Resort on Wednesday evening following an ...

Two 18-year-old men and a juvenile from New Haven were arrested in Bristol on Tuesday after abandoning a stolen vehicle ...

Suzanne Laprise faces a 12-year prison sentence after pleading guilty to attempted first-degree assault in a shooting in the ...

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...

Voting took place on February 4 at student union meetings at both Bristol University and Imperial College London. Other ...